The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Is there a role for anti-IgE in combination with specific allergen immunotherapy?
Abstract
PURPOSE OF REVIEW: A line of novel therapeutic approaches that try to interfere more specifically with the immunological mechanisms underlying allergen-induced pathology are currently undergoing clinical evaluation. The most advanced of these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate type hypersensitivity reactions. In addition, a lot of interest has recently been focused on allergen-specific immunotherapy due to its potential to cure allergic diseases. In the present review, state-of-the-art treatment of allergic diseases with anti-IgE and allergen-specific immunotherapy is summarized, and the potential of combination therapy with both treatment options is discussed. RECENT FINDINGS: Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity. This treatment has been successfully tested in patients with allergic rhinitis, asthma and food allergy, showing significant efficacy in reducing symptom scores and rescue medication use. Anti-IgE therapy is limited by high costs and the necessity for permanent or every-season treatment. The strongest argument in favor of allergen-specific immunotherapy is the potential to cure allergic diseases, which has been demonstrated in patients with allergic rhinitis, insect venom allergy and, to a lesser degree, asthma. The broader application of allergen-specific immunotherapy is restricted by sometimes life-threatening side effects. A combination of anti-IgE and allergen-specific immunotherapy was shown to be superior to each single treatment protocol in children and adolescents with allergic rhinitis, as demonstrated by efficacy of symptom scores and rescue medication use. SUMMARY: There are strong arguments for a combination of anti-IgE plus allergen-specific immunotherapy for treatment of allergic diseases: improved efficacy, limited side effects, and potential curative effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While both modalities have independently demonstrated efficacy as treatment options, improved strategies are needed, especially in patients with multiple sensitizations.1733”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1733]
Citations
Cites
Johansson, S. G. O., Hourihane, J. O., Bousquet, J., Bruijnzeel-Koomen, C., Dreborg, S., Haahtela, T., Kowalski, M. L., Mygind, N., Ring, J., van Cauwenberge, P., et al. (2001) · Allergy · doi:10.1034/j.1398-9995.2001.t01-1-00001.x · Cited by 1,723
Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper
Bousquet, J., Lockey, R., & Malling, H.-J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70271-4 · Cited by 1,581
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
(1998) · European Respiratory Journal · doi:10.1183/09031936.98.12020315 · Cited by 1,102
Möller, C., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Jacobsen, L., Koivikko, A., Koller, D. Y., Niggemann, B., Norberg, L. A., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121317 · Cited by 1,065
Self-citationSolèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
MacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
Research works printed but not linked: 4
- Fox, 1996, J Pharmacol Exp Ther, 279, 1000
- Malone, 1997, J Allergy Clin Immunol, 99, 22
- 2003, Ann Allergy Asthma Immunol, 90, 1
- Varney, 1997, Clin Exp Allergy, 27, 860, 10.1111/j.1365-2222.1997.tb01225.x · doi:10.1111/j.1365-2222.1997.tb01225.x · Paper page
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Egg oral immunotherapy in nonanaphylactic children with egg allergy
Buchanan, A. D., Green, T. D., Jones, S. M., Scurlock, A. M., Christie, L., Althage, K. A., Steele, P. H., Pons, L., Helm, R. M., Lee, L. A., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.016 · Cited by 400
Klunker, S., Saggar, L. R., Seyfert-Margolis, V., Asare, A. L., Casale, T. B., Durham, S. R., & Francis, J. N. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.05.034 · Cited by 129
“of subjects 7 11 9 9 Age (y) 39 (29-43) 44 (41-48) 32 (29-41) 41 (38-46) M/F 4/3 0/11 4/5 4/5 Total IgE (IU/mL) 55 (37-132) 26 (16-41) 112 (78-187) 44 (24-65) Ragweed skin test (mm) Wheal response 8 (6-11) 8 (7-10) 9 (6-11) 9 (6-9) Erythema response 28 (17-38) 34 (25-40) 28 (18-49) 27 (22-36)”
Rolinck‐Werninghaus, C., Hamelmann, E., Keil, T., Kulig, M., Koetz, K., Gerstner, B., Kuehr, J., Zielen, S., Schauer, U., Kamin, W., et al. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00552.x · Cited by 120
“The lack of efficacy of SIT in the first year(s) of treatment, however, may be overcome by combination with anti-IgE treatment that acts nonallergen-specific and rapidly unfolds its antiallergic properties (23).”
BackgroundSelf-citationAnti-IgE for the Treatment of Allergic Rhinitis – and Eventually Nasal Polyps?
Verbruggen, K., Cauwenberge, P. V., & Bachert, C. (2008) · International Archives of Allergy and Immunology · doi:10.1159/000155739 · Cited by 86
Metadata
- Authors
- Hamelmann, E., Rolinck-Werninghaus, C., & Wahn, U.
- Affiliations
- Humboldt-Universität zu Berlin (DE)
- Corresponding author
- Hamelmann, Eckard
- Venue
- Current Opinion in Allergy and Clinical Immunology
- Published
- 2003-12
- Volume
- 3
- Issue
- 6
- Pages
- 501-510
- ISSN
- 1473-6322 (ISSN-L)
- 1528-4050
- OpenAlex
- W2024619992
- Cited by
- 25
- References
- 58
- Citations by year
- 2019: 1 · 2018: 2 · 2015: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- anti-IgE therapy, allergen immunotherapy, combination therapy, allergic rhinitis, asthma, food allergy, insect venom allergy, immediate hypersensitivity, rescue medication use, children and adolescents
- MeSH terms
- Antibodies, Anti-Idiotypic, Asthma, Clinical Trials as Topic, Desensitization, Immunologic, Humans, Hypersensitivity, Immunoglobulin E, Rhinitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there a role for anti-IgE in combination with specific allergen immunotherapy? https://app.cochat.ai/papers/10.1097/00130832-200312000-00013
- The paper
- Hamelmann, E., Rolinck-Werninghaus, C., & Wahn, U. (2003). Is there a role for anti-IgE in combination with specific allergen immunotherapy? Current Opinion in Allergy and Clinical Immunology. https://doi.org/10.1097/00130832-200312000-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.